Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 -0.54%90 Return-on-Tangible-Equity is 11.45% as of Jun. 2026, which is 48% below its 10-year median of 21.88. GuruFocus rates BOM:543960 with a GF Score™ of 90/100 and a GF Value™ of ₹1,635.14 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,196 Biotechnology companies, Concord Biotech ranks better than 89.21% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Concord Biotech's annualized net income for the quarter that ended in Jun. 2026 was ₹2,308 Mil. Concord Biotech's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₹20,152 Mil. Therefore, Concord Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 11.45%.
The historical rank and industry rank for Concord Biotech's Return-on-Tangible-Equity or its related term are showing as below:
BOM:543960'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 13.64 Med: 21.88 Max: 26.64
Current: 14.5
During the past 7 years, Concord Biotech's highest Return-on-Tangible-Equity was 26.64%. The lowest was 13.64%. And the median was 21.88%.
BOM:543960's Return-on-Tangible-Equity is ranked better than 89.21% of 1196
companies
in the Biotechnology industry
Industry Median: -43.11
vs BOM:543960: 14.50
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Concord Biotech Return-on-Tangible-Equity Related Terms
Concord Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Concord Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.45% mean?
Concord Biotech (BOM:543960) has a Return-on-Tangible-Equity of 11.45% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Concord Biotech and its competitors. This is 48% below median its historical median of 21.88. Over the past decade, Concord Biotech's Return-on-Tangible-Equity has ranged from 13.64 to 26.64. According to the industry distribution chart, Concord Biotech ranks #129 out of 1196 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Concord Biotech's Return-on-Tangible-Equity too high?
Concord Biotech's current Return-on-Tangible-Equity of 11.45% is 48% below median its 10-year median of 21.88. Over the past 10 years, this metric has ranged from a low of 13.64 to a high of 26.64. Based on the distribution chart, Concord Biotech ranks #129 out of 1196 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #129 out of 1196 companies for Return-on-Tangible-Equity. This places Concord Biotech in the top 11% of its industry — outperforming the majority of peers. Historically, Concord Biotech's own Return-on-Tangible-Equity has ranged from 13.64 to 26.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Concord Biotech and its competitors. Concord Biotech's current Return-on-Tangible-Equity is 11.45%, which is 48% below median its own 10-year median of 21.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,635.14, compared to a current price of ₹1,367.60 — trading 16.4% below its estimated fair value. The current Return-on-Tangible-Equity is 11.45%, which is 48% below median its 10-year median of 21.88. Concord Biotech's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Return-on-Tangible-Equity is 11.45% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,367.60 is trading 16.4% below its estimated GF Value™ of ₹1,635.14.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
Return-on-Tangible-Equity: 11.45% (48% below median its 10-year median of 21.88)
GF Value™: ₹1,635.14 vs. price of ₹1,367.60 (16.4% below fair value)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
90GF Score
Get the complete analysis for BOM:543960
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
